Eli Lilly’s strategy for launching its oral obesity treatment, Foundayo, in Europe will be significantly influenced by the implications of the most favored nations (MFN) deal it signed with the U.S. last year. Patrik Jonsson, the company’s International chief, revealed to Reuters that the pricing outcomes of this agreement will play a crucial role in determining how Foundayo is marketed and sold across European markets.
This focus on telehealth as a primary sales channel reflects a broader trend within the pharmaceutical industry, where digital health solutions are increasingly being integrated into treatment strategies. By leveraging telehealth, Lilly aims to enhance accessibility and patient engagement, which are vital in the competitive landscape of obesity treatments. The MFN deal’s pricing constraints may necessitate innovative approaches to market entry, positioning Lilly to navigate regulatory environments effectively while maximizing its product’s reach.
Get started today with Solo access →
